Imidacloprid是一种具有内吸活性的新烟碱类杀虫剂。
Cas No.:138261-41-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Imidacloprid is a neonicotinoid insecticide with systemic activity. Imidacloprid acts as a false neurotransmitter by binding to nicotinic acetylcholine receptors in the insect nervous system, disrupting normal nerve transmission, keeping the nerve channels open, causing abnormal excitation, paralysis, and death in insects. Imidacloprid can be used in research related to neurotoxicity, cytotoxicity, and metabolic interference[1-4].
In vitro, Imidacloprid (0.46-23μM) was used to treat human prostate epithelial WPM-Y.1 cells for 24 hours. Imidacloprid significantly induced cytotoxicity, oxidative stress, increased lactate dehydrogenase (LDH) activity, elevated malondialdehyde (MDA) levels, decreased glutathione (GSH) content, reduced glutathione-S-transferase (GST) activity, increased activities of catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR), and caused ultrastructural defects such as organelle destruction, irregular nuclear membrane, chromatin migration, increased vacuoles, and reduced mitochondria[5]. Imidacloprid (1-500μg) was used to treat L-929 fibroblast cells for 24 hours. Imidacloprid (500μg) significantly increased L-929 cell lactate dehydrogenase (LDH) levels, decreased glutathione (GSH) levels, and had no significant effect on acetylcholinesterase (AChE) levels[6].
In vivo, Imidacloprid (0.06, 0.6, or 6mg/kg/day) was administered via diet for 12 weeks to female C57BL/6J mice fed a low-fat (4% w/w) or high-fat (20% w/w) diet. Imidacloprid significantly enhanced high-fat diet-induced weight gain and obesity and increased serum insulin levels[7]. Imidacloprid (5 and 20mg/kg/day) was administered via repeated oral gavage for 28 days to female KM mice. Imidacloprid (20mg/kg/day) significantly caused hippocampal formation cell band loss, liver vascular swelling, disordered hepatic cord arrangement, hepatocyte necrosis and nuclear pyknosis, and increased plasma ALT, AST, and AKP levels; Imidacloprid (5mg/kg/day) significantly altered the metabolic profiles of the hippocampus and liver, involving lipid metabolism, amino acid metabolism, nucleotide metabolism, carbohydrate metabolism, and energy metabolism pathways[8].
References:
[1] Gautam P, Kumar Dubey S. Biodegradation of imidacloprid: Molecular and kinetic analysis. Bioresour Technol. 2022 Apr;350:126915.
[2] Bhende RS, Dafale NA. Insights into the ubiquity, persistence and microbial intervention of imidacloprid. Arch Microbiol. 2023 May 2;205(5):215.
[3] Fouad MR, Abdel-Raheem SAA. An overview on the fate and behavior of imidacloprid in agricultural environments. Environ Sci Pollut Res Int. 2024 Nov;31(52):61345-61355.
[4] Mikolić A, Karačonji IB. Imidacloprid as reproductive toxicant and endocrine disruptor: investigations in laboratory animals. Arh Hig Rada Toksikol. 2018 Jun 1;69(2):103-108.
[5] Abdel-Halim KY, Osman SR. Cytotoxicity and Oxidative Stress Responses of Imidacloprid and Glyphosate in Human Prostate Epithelial WPM-Y.1 Cell Line. J Toxicol. 2020 Dec 8;2020:4364650.
[6] Sevİm Ç, Taghİzadehghalehjoughİ A, Kara M. In Vitro Investigation of the Effects of Imidacloprid on AChE, LDH, and GSH Levels in the L-929 Fibroblast Cell Line. Turk J Pharm Sci. 2020 Oct;17(5):506-510.
[7] Sun Q, Qi W, Xiao X, et al. Imidacloprid Promotes High Fat Diet-Induced Adiposity in Female C57BL/6J Mice and Enhances Adipogenesis in 3T3-L1 Adipocytes via the AMPKα-Mediated Pathway. J Agric Food Chem. 2017 Aug 9;65(31):6572-6581.
[8] Zheng M, Qin Q, Zhou W, et al. Metabolic disturbance in hippocampus and liver of mice: A primary response to imidacloprid exposure. Sci Rep. 2020 Mar 31;10(1):5713.
Imidacloprid是一种具有内吸活性的新烟碱类杀虫剂。Imidacloprid通过作为错误的神经递质与昆虫神经系统的烟碱型乙酰胆碱受体结合，干扰正常神经传导，使神经传输保持开放状态，引起昆虫异常兴奋和麻痹死亡。Imidacloprid可用于神经毒性、细胞毒性、干扰代谢等相关研究[1-4]。
在体外，Imidacloprid（0.46-23μM）处理人前列腺上皮WPM-Y.1细胞24小时。Imidacloprid显著诱导细胞毒性、氧化应激、乳酸脱氢酶（LDH）活性增加、丙二醛（MDA）水平升高、谷胱甘肽（GSH）含量降低、谷胱甘肽-S-转移酶（GST）活性降低、过氧化氢酶（CAT）、谷胱甘肽过氧化物酶（GPx）、谷胱甘肽还原酶（GR）活性增加，并导致超微结构缺陷如细胞器破坏、核膜不规则、染色质迁移、空泡增加、线粒体减少[5]。Imidacloprid（1-500μg）处理L-929成纤维细胞24h。Imidacloprid（500μg）显著增加L-929细胞乳酸脱氢酶（LDH）水平，下降低谷胱甘肽（GSH）水平，对乙酰胆碱酯酶（AChE）水平无显著影响[6]。
在体内，Imidacloprid（0.06、0.6或6mg/kg/day）通过饮食给药持续12周，用于处理喂食低脂（4% w/w）或高脂（20% w/w）饲料的雌性C57BL/6J小鼠。Imidacloprid显著增强了高脂饮食诱导的体重增加和肥胖，并增加了血清胰岛素水平[7]。Imidacloprid（5和20mg/kg/day）通过重复口服给药持续28天，用于处理雌性KM小鼠。Imidacloprid（20mg/kg/day）显著导致海马形成细胞带缺失、肝脏血管肿胀、肝索排列紊乱、肝细胞坏死和核固缩，并增加血浆ALT、AST和AKP水平；Imidacloprid（5mg/kg/day）显著改变海马和肝脏的代谢谱，涉及脂质代谢、氨基酸代谢、核苷酸代谢、碳水化合物代谢和能量代谢途径[8]。
| Cell experiment [1]: | |
Cell lines | WPM-Y.1 cells (human prostate epithelial cell line) |
Preparation Method | WPM-Y.1 cells were maintained in DEMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in a 5% CO₂ atmosphere. Cells were seeded at a concentration of 1×10⁴ cells/ml and treated with Imidacloprid (0.46-23μM) for 24 hours. |
Reaction Conditions | 0.46-23μM; 24h |
Applications | Imidacloprid significantly decreased cell viability, increased lactate dehydrogenase (LDH) activity and malondialdehyde (MDA) level, decreased glutathione (GSH) content and glutathione-S-transferase (GST) activity, and increased activities of catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR). Transmission electron microscopy showed significant defects including organelle destruction, irregular nuclear membrane, chromatin migration, increased vacuoles, and reduced mitochondria. |
| Animal experiment [2]: | |
Animal models | Female C57BL/6J mice |
Preparation Method | Mice were fed a low-fat (4% w/w) or high-fat (20% w/w) diet containing Imidacloprid (0.06, 0.6, or 6mg/kg/day) for 12 weeks. Water and diet were given ad libitum. At the end of the experiment, mice were fasted for 4h before being sacrificed by CO₂ asphyxiation. |
Dosage form | 0.06, 0.6, or 6mg/kg/day; i.p.; dietary administration; 12 weeks |
Applications | Imidacloprid significantly enhanced high-fat diet-induced weight gain and adiposity, increased serum insulin levels, and inhibited AMPKα activation in white adipose tissue. Imidacloprid increased serum leptin levels and adipocyte size in high-fat diet-fed mice. |
References: | |
| Cas No. | 138261-41-3 | SDF | |
| 别名 | 吡虫啉 | ||
| Canonical SMILES | O=[N+](/N=C1NCCN\1CC2=CC=C(Cl)N=C2)[O-] | ||
| 分子式 | C9H10ClN5O2 | 分子量 | 255.66 |
| 溶解度 | DMSO : ≥ 300 mg/mL (1173.43 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9114 mL | 19.5572 mL | 39.1144 mL |
| 5 mM | 782.3 μL | 3.9114 mL | 7.8229 mL |
| 10 mM | 391.1 μL | 1.9557 mL | 3.9114 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet